Clinico-Biological and Histological Predictive Factors and Markers of Response to Everolimus in Neuroendocrine Tumors

#1032

Introduction: Several systemic treatments are available for metastatic neuroendocrine Tumors (NETs), including everolimus, but there is no predictive factor of response to these treatments.

Aim(s): Our aim was to identify clinico-biological and histological markers of response to everolimus.

Materials and methods: We retrospectively reviewed 53 patients with NETs treated by everolimus. Markers of mTOR pathway (p-p70S6K) and angiogenesis (endoglin, CD34) were studied by immunohistochemistry. Prognostic factors of PFS were studied by Kaplan Meier analysis. Good responders (PFS> 12 months) were compared to poor responders (PFS<6 months).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Walter T

Authors: Benslama N, Bollard J, Vercherat C, Roche C, Hervieu V,

Keywords: neuroendocrine tumors, everolimus, markers, p-p70S6K,